Publication | Closed Access

Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer

Integrin α3Breast OncologyDrug TargetingMedicineBreast CancerMtor Inhibitor RapamycinTriple-negative Breast CancerAnti-cancer AgentCancer TreatmentTumor TargetingPharmacologyRadiation OncologyTumor Biology